Enterprise Value

167.2B

Cash

34.25B

Avg Qtr Burn

N/A

Short % of Float

1.19%

Insider Ownership

0.24%

Institutional Own.

79.33%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BLINCYTO® (blinatumomab) Details
B-cell acute lymphoblastic leukemia

Approved

Quarterly sales

Approved

Quarterly sales

TAVNEOS (Avacopan) (C5aR) Details
ANCA-Associated Vasculitis, Autoimmune disease

Approved

Quarterly sales

TEPEZZA Details
Eye disease , Thyroid Eye Disease

Approved

Quarterly sales

KRYSTEXXA Details
Chronic refractory gout

Approved

Quarterly sales

LUMAKRAS/LUMYKRAS Details
Non-small cell lung carcinoma

PDUFA

Approval decision

Phase 3

Data readout

Phase 3

Data readout

TAVNEOS (Avacopan) (C5aR) Details
Hidradenitis suppurativa, Skin disease/disorder

Phase 3

Update

Phase 3

Initiation

HZN-825 Details
Idiopathic pulmonary fibrosis

Phase 2b

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Dazodalibep (HZN-4920) Details
Kidney disease, Lupus nephritis, Autoimmune disease

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

UPLIZNA (Inebilizumab-cdon) (Anti-CD19 mAb) Details
Kidney transplantation, Kidney disease

Phase 2

Data readout

Dazodalibep (HZN-4920) (VIB4920) (Anti-CD40L-Tn3 Fusion Protein) Details
Arthritis, Genetic disorder, Congenital adrenal hyperplasia, Rheumatoid arthritis, Autoimmune disease

Phase 2

Update

TAVNEOS (Avacopan) (C5aR) Details
C3 Glomerulopathy, Kidney disease

Phase 2

Update

Phase 2

Update

HZN-457 Details
Chronic refractory gout

Phase 1

Data readout